Literature DB >> 11943218

Targeted cytosolic delivery of hydrogel nanoparticles into HepG2 cells through engineered Sendai viral envelopes.

Siddhartha S Jana1, Dhruba J Bharali, Prashant Mani, Amarnath Maitra, Chhitar M Gupta, Debi P Sarkar.   

Abstract

Hydrogel nanoparticles of cross-linked polyvinylpyrrolidone (PVP-NP) (35-50 nm in diameter) containing fluoresceinated dextran (FITC-Dx) were encapsulated in reconstituted Sendai viral envelopes containing only the fusion (F) protein (F-virosomes(1)). Incubation of these loaded F-virosomes with human hepatoblastoma cells (HepG2) in culture resulted in membrane-fusion-mediated delivery of NPs to the cell cytoplasm, as inferred from the ability of cells to internalize FITC-Dx loaded PVP-NP (PVP(f)-NP) in the presence of azide (an inhibitor of the endocytotic process). Introduction of PVP(f)-NP into the HepG2 cells was assured by selective accumulation of FITC fluorescence in the cytosolic compartment. The structural integrity of the internalized PVP(f)-NP was also confirmed by fluorescence microscopy and ultracentrifugation analysis. The potential usefulness of PVP-NP-mediated cytosolic release of water soluble drugs both in vitro and in vivo has been established for the first time.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943218     DOI: 10.1016/s0014-5793(02)02467-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

Review 1.  Gene therapy in India: a focus.

Authors:  Sarvani Chodisetty; Everette Jacob Remington Nelson
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

2.  Preparation and characterization of nanocurcumin based hybrid virosomes as a drug delivery vehicle with enhanced anticancerous activity and reduced toxicity.

Authors:  Varun Kumar; Ramesh Kumar; V K Jain; Suman Nagpal
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

3.  Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo.

Authors:  Coleen R Kaiser; Michelle L Flenniken; Eric Gillitzer; Ann L Harmsen; Allen G Harmsen; Mark A Jutila; Trevor Douglas; Mark J Young
Journal:  Int J Nanomedicine       Date:  2007

4.  Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mroczek-Musulman; Alicia M Waters; Jennifer M Coleman; Virginia Kelly; James M Markert; G Yancey Gillespie; Gregory K Friedman; Elizabeth A Beierle
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.